Bausch + Lomb Corporation (BLCO) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Analyst target reached at $16.20 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Vision Care (57.0%).
Bausch + Lomb is a fully integrated eye health company with ~$5.1B in 2025 revenues across Vision Care (57%), Pharmaceuticals (25%), and Surgical (18%) segments, sold in ~100 countries with ~13,000 employees and ~400 products. It is 88%-owned by Bausch Health Companies (BHC),... Read more
Sell if holding. Analyst target reached at $16.20 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Vision Care (57.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Bausch + Lomb Corporation
Latest news
- Bausch + Lomb Corporation 2026 Q1 - Results - Earnings Call Presentation (NYSE:BLCO) 2026-04-29 - Seeking Alpha — Seeking Alpha neutral
- Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance — Yahoo Finance positive
- Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026 - StockStory — StockStory positive
- Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026 - TradingView — TradingView positive
- Is It Time To Reconsider Bausch + Lomb (BLCO) After Its 28% One-Year Rally? - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductVision Care57%10-K Item 1: 'Vision Care | | $ | 2,923 | | | 57 | % | | $ | 2,739 | | | 57 | %'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $16.20 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Vision Care (57.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $15.32. Score 5.6/10, moderate confidence.
Take-profit target: $16.08 (-0.7% upside). Prior stop was $15.32. Stop-loss: $15.32.
Concentration risk — Product: Vision Care (57.0%); Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1).
Bausch + Lomb Corporation trades at a P/E of N/A (forward 15.2). TrendMatrix value score: 6.9/10. Verdict: Sell.
19 analysts cover BLCO with a consensus score of 3.6/5. Average price target: $18.
What does Bausch + Lomb Corporation do?Bausch + Lomb is a fully integrated eye health company with ~$5.1B in 2025 revenues across Vision Care (57%),...
Bausch + Lomb is a fully integrated eye health company with ~$5.1B in 2025 revenues across Vision Care (57%), Pharmaceuticals (25%), and Surgical (18%) segments, sold in ~100 countries with ~13,000 employees and ~400 products. It is 88%-owned by Bausch Health Companies (BHC), which controls the business direction; a separation from BHC is being evaluated.